Advertisement

Topics

Merck, Generex to assess Keytruda in combination with AE37

04:57 EDT 2 Aug 2017 | Pharmaceutical Business Review

Generex Biotechnology's subsidiary, Antigen Express has signed a clinical trial collaboration agreement with Merck, via a wholly-owned subsidiary, to assess Antigen’s AE37 cancer vaccine in combination with Merck’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA (pembrolizumab), in patients with metastatic triple-negative breast cancer.

Original Article: Merck, Generex to assess Keytruda in combination with AE37

NEXT ARTICLE

More From BioPortfolio on "Merck, Generex to assess Keytruda in combination with AE37"

Quick Search
Advertisement
 

Relevant Topics

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...